67 results found.

HIV-1 Infection Clinical Trial using Raltegravir

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (ò 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany.
Raltegravir

HIV Infections Clinical Trial using Methotrexate (MTX); Placebo; Folic acid

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 40 years or older.
- Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection.
Methotrexate (MTX); Placebo; Folic acid

Tuberculosis, or HIV Infections Clinical Trial using Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 13 years or older.
- Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection.
Rifapentine (RPT); Isoniazid (INH); Pyridoxine (Vitamin B6)

Human Immunodeficiency Virus-type 1 Infection Clinical Trial using Rilpivirine; Efavirenz; Tenofovir disoproxil fumarate; Emtricitabine

Janssen-Cilag International NV - Recruiting 18 years or older.
- A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF).
Rilpivirine; Efavirenz; Tenofovir disoproxil fumarate; Emtricitabine

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

HIV-1 Infection Clinical Trial

University of North Carolina, Chapel Hill - Recruiting 18 years or older.
- CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF.

HIV Infection Clinical Trial using Vitamin D3 (cholecalciferol); Placebo

Harvard School of Public Health - Recruiting 18 years or older.
- Trial of Vitamin D in HIV Progression.
Vitamin D3 (cholecalciferol); Placebo

HIV-1 Infection Clinical Trial using BMS-955176; Placebo matching with BMS-955176; Atazanavir; Ritonavir; Tenofovir; Emtricitabine

Bristol-Myers Squibb - Recruiting 18 years to 55 years.
- Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects.
BMS-955176; Placebo matching with BMS-955176; Atazanavir; Ritonavir; Tenofovir; Emtricitabine

HIV Infection Clinical Trial using Maraviroc; Emtricitabine; Tenofovir disoproxil fumarate; Maraviroc placebo; Emtricitabine placebo; Tenofovir disoproxil fumarate placebo

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years or older.
- A Phase II Randomized, Double-Blind, Study of the Safety and Tolerability of Maraviroc (MVC), Maraviroc + Emtricitabine (MVC+FTC), Maraviroc + Tenofovir Disoproxil Fumarate (MVC+TDF), or Tenofovir Disoproxil Fumarate + Emtricitabine (TDF+FTC) For Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission in At-Risk Men Who Have Sex With Men and in At-Risk Women.
Maraviroc; Emtricitabine; Tenofovir disoproxil fumarate; Maraviroc placebo; Emtricitabine placebo; Tenofovir disoproxil fumarate placebo

HIV Infection Clinical Trial using Tenofovir, Emtricitabine, Lopinavir/r; Tenofovir, Emtricitabine, Raltegravir

Hospital Clinic of Barcelona - Recruiting 18 years or older.
- Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: Tenofovir + Emtricitabine + Lopinavir/Ritonavir Versus Tenofovir + Emtricitabine + Raltegravir.
Tenofovir, Emtricitabine, Lopinavir/r; Tenofovir, Emtricitabine, Raltegravir

HIV Infection Clinical Trial using Tenofovir, emtricitabine, maraviroc; Tenofovir, emtricitabine, lopinavir/r

Hospital Clinic of Barcelona - Recruiting 18 years or older.
- Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1: TENOFOVIR+EMTRICITABINA + LOPINAVIR/RITONAVIR VS TENOFOVIR+EMTRICITABINA + MARAVIROC.
Tenofovir, emtricitabine, maraviroc; Tenofovir, emtricitabine, lopinavir/r

Anal Cancer, Nonneoplastic Condition, Penile Cancer, or Precancer Clinical Trial using quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; laboratory biomarker analysis

AIDS Malignancy Clinical Trials Consortium - Recruiting 13 years to 26 years.
- AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males.
quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; laboratory biomarker analysis

HIV, or Therapeutic Vaccine Clinical Trial using HIV-1 Multiantigen pDNA Vaccine; Human IL-12 pDNA; In Vivo Electroporation using the TriGri; rVSVIN HIV Gag Vaccine; Placebo

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 65 years.
- A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection.
HIV-1 Multiantigen pDNA Vaccine; Human IL-12 pDNA; In Vivo Electroporation using the TriGri; rVSVIN HIV Gag Vaccine; Placebo

HIV Infection, or Kaposi's Sarcoma Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer.

HIV Infections, AIDS, or Opportunistic Infections Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection.

HIV Infection, or Neoplasm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years to 17 years.
- Psychological Benefits of a Normalized Camping Experience for Children With Cancer.

Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficie Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 14 years or older.
- Characterization and Management of Patients With HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy.

Tuberculosis, HIV, or IRIS Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Transcriptional Signature of HIV And TB Co-Infection.

HIV Infection Clinical Trial using Hydroxychloroquine

St Stephens Aids Trust - Recruiting 18 years to 65 years.
- The Immunological Impact of Adding Hydroxychloroquine in Patients With Discordant CD4+ Cell Responses to Suppressive HAART: A Phase I Pilot Study..
Hydroxychloroquine

Cancer, HIV Infection, or Skin Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI) Center for Cancer Research (CCR) Clinical Protocols.

Parkinson's Disease, or HIV Infections Clinical Trial

KineMed - Recruiting 18 years or older.
- Cellular and Molecular Kinetics of Cerebrospinal Fluid (CSF) Using Heavy Water Labeling Method: A Study of Healthy Controls, CNS HIV Infection, Parkinson's Disease and Other Neurodegenerative Diseases.

Hepatitis C, Chronic, or Human Immunodeficiency Virus Clinical Trial using DAA against HCV

Valme University Hospital - Recruiting 18 years or older.
- Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
DAA against HCV

Papillomavirus Infections, or HIV Infections Clinical Trial using Oral swabs for HPV-typing and high-risk HPV-determination

Deutsche Luft und Raumfahrt - Recruiting 18 years or older.
- Incidence, Prevalence, Spectrum of HPV-types, and Viral Load Determination of High-risk Human Papillomavirus Infection of the Oral Cavity in HIV-infected Men Who Have Sex With Men.
Oral swabs for HPV-typing and high-risk HPV-determination

HIV Infection Clinical Trial using 3MV; PCC; Emtricitabine/tenofovir (FTC/TDF (Truvadar))

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) - Recruiting 15 years to 17 years.
- Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States.
3MV; PCC; Emtricitabine/tenofovir (FTC/TDF (Truvadar))

Heart Diseases, or HIV Clinical Trial

University Hospital, Bonn - Recruiting 18 years or older.
- Myocardial T1-mapping and T1-derived Extracellular Volume Fraction (ECV) in HIV-infection Patients With Chronic High and Low CD4+ Counts and in a Healthy Control Group.

HIV Infection Clinical Trial using Micronutrients and antioxidants; Multivitamins and minerals

Ottawa Hospital Research Institute - Recruiting 18 years or older.
- A Randomized Control Clinical Trial Of Micronutrient & Antioxidant Supplementation in Persons With Untreated HIV Infection.
Micronutrients and antioxidants; Multivitamins and minerals

HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Clinical Trial using VRC-HIVMAB060-00-AB

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 50 years.
- VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults.
VRC-HIVMAB060-00-AB

Atherosclerosis Clinical Trial

University of California, San Francisco - Recruiting 18 years to 65 years.
- Immunologic and Inflammatory Factors and Cardiovascular Risk in Patients With HIV Infection or Autoimmune Diseases.

HIV Infection Clinical Trial

Merck Sharp & Dohme Corp. - Recruiting 3 years or older.
- Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of STOCRIN in Usual Practice.

HIV-1 Infection Clinical Trial

Gen-Probe, Incorporated - Recruiting 15 years or older.
- Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay.

HIV-1 Infection Clinical Trial using Vorinostat

University of North Carolina, Chapel Hill - Recruiting 18 years to 65 years.
- A Phase I/II Investigation of the Effect of Vorinostat (VOR) on HIV RNA Expression in the Resting CD4+ T Cells of HIV-Infected Patients Receiving Stable Antiretroviral Therapy.
Vorinostat

HIV Infection, Cardiovascular Disease, or Inflammation Clinical Trial

University of California, San Francisco - Recruiting 40 years to 80 years.
- The Role of Inflammation and Aging in HIV-Associated Cardiovascular Risk.

HIV Clinical Trial using VAC-3S

InnaVirVax - Recruiting 18 years to 60 years.
- Assessment of the Therapeutic Properties of the VAC-3S Immunoprotective Vaccine When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study.
VAC-3S

HIV Infection Clinical Trial using Bruthas Project; Standard HIV Testing and Counseling

University of California, San Francisco - Recruiting 18 years to 65 years.
- A Randomized Controlled Trial of the Bruthas Project.
Bruthas Project; Standard HIV Testing and Counseling

HIV Infection Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-Infected and HIV-Uninfected Volunteers.

HIV-1 Infection Clinical Trial using Part A: lenalidomide dose escalation; Part B: lenalidomide; Part B: lenalidomide placebo

Bionor Immuno AS - Recruiting 18 years to 55 years.
- A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART)..
Part A: lenalidomide dose escalation; Part B: lenalidomide; Part B: lenalidomide placebo

Immunodeficiency, Mycobacterial Infection, or Opportunistic Infec Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma.

Hepatitis, HIV, or Liver Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Natural History of Liver Disease in a Cohort of Participants With Hepatitis B and/or Hepatitis C With or Without HIV Infection.

HIV Infection Clinical Trial using atazanavir 300mg boosted with ritonavir 50 mg

Ottawa Hospital Research Institute - Recruiting 18 years to 70 years.
- Microboosting of Atazanavir 300 mg With 50 mg Versus 100 mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study.
atazanavir 300mg boosted with ritonavir 50 mg

HIV Infection Clinical Trial

Gilead Sciences - Recruiting N/A or older.
- A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication Nested in the Antiretroviral Pregnancy Registry.

Anal Cancer, HIV Infection, or Human Papilloma Virus Infection Clinical Trial using comparison of screening methods; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

AIDS Malignancy Clinical Trials Consortium - Recruiting 18 years or older.
- Screening HIV-Infected Women for Anal Cancer Precursors.
comparison of screening methods; laboratory biomarker analysis; questionnaire administration; quality-of-life assessment

HIV-1 Infection Clinical Trial using Placebos of GTU-multiHIV B and LIPO-5 vaccines; GTU-multHIV B vaccine and LIPO-5 vaccine

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years to 59 years.
- Evaluation of a Therapeutic Immunization Strategy Associating a DNA Vaccine (GTU-MultiHIV B) Followed by a Lipopeptide Vaccine (LIPO-5) in the Control of Viral Replication Following Antiretroviral Treatment Interruption in HIV-1 Infected Patients With a CD4 Cell Count ò 600/mm3.
Placebos of GTU-multiHIV B and LIPO-5 vaccines; GTU-multHIV B vaccine and LIPO-5 vaccine

HIV Infection Clinical Trial using adherence reinforcement; Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years or older.
- Systematic 'Adherence Intervention' Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study..
adherence reinforcement; Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)

Pulmonary Arterial Hypertension, HIV Infection, Congenital Heart Clinical Trial using skin biopsy; Blood Sample

Assistance Publique - H“pitaux de Paris - Recruiting 18 years or older.
- Auto-immunity and Prognosis of Pulmonary Arterial Hypertension.
skin biopsy; Blood Sample

Infection, Human Immunodeficiency Virus Clinical Trial using Dolutegravir/abacavir/lamivudine FDC; Atazanavir; Ritonavir; Tenofovir/emtricitabine FDC

ViiV Healthcare - Recruiting 18 years or older.
- A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Na‹ve Women.
Dolutegravir/abacavir/lamivudine FDC; Atazanavir; Ritonavir; Tenofovir/emtricitabine FDC

HIV-1 Infection, or Pf Subclinical Parasitemia Clinical Trial using Lopinavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate; Efavirenz; Nevirapine; emtricitabine/tenofovir disoproxil fumarate; trimethoprim/sulfamethoxazole

AIDS Clinical Trials Group - Recruiting 18 years or older.
- An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <350 Cells/mm3.
Lopinavir/ritonavir; Emtricitabine/tenofovir disoproxil fumarate; Efavirenz; Nevirapine; emtricitabine/tenofovir disoproxil fumarate; trimethoprim/sulfamethoxazole

HIV Infection Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid.

HIV Infections Clinical Trial using Emtricitabine (FTC); Tenofovir disoproxil fumarate (TDF); Efavirenz (EFV); Truvada

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 55 years.
- Cellular Pharmacology of Tenofovir and Emtricitabine for HIV Prophylaxis (Cell Prep).
Emtricitabine (FTC); Tenofovir disoproxil fumarate (TDF); Efavirenz (EFV); Truvada

HIV-1 Infection Clinical Trial using Raltegravir; Efavirenz

Taipei Veterans General Hospital, Taiwan - Recruiting 20 years to 60 years.
- An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-na‹ve Patients With HIV-1 Infection.
Raltegravir; Efavirenz

Chronic Hepatitis C Infection Clinical Trial using Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

Bristol-Myers Squibb - Recruiting 18 years or older.
- Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment na‹ve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV.
Pegylated Interferon Lambda-1a; Daclatasvir (DCV); Ribasphere (RBV)

HIV, or Human Immunodeficiency Virus Clinical Trial using Disulfiram

University of California, San Francisco - Recruiting 18 years or older.
- Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study.
Disulfiram

Chronic HIV Infection, or HCV Coinfection Clinical Trial using Fosamprenavir

Fundacion SEIMC-GESIDA - Recruiting 18 years or older.
- Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
Fosamprenavir

HIV-2 Infection Clinical Trial using emtricitabine / tenofovir disoproxil fumarate / raltegravir .

French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) - Recruiting 18 years or older.
- ANRS 159 VIH-2 : Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients.
emtricitabine / tenofovir disoproxil fumarate / raltegravir .

Human Immunodeficiency Virus Clinical Trial using TwHF; placebo treatment

Beijing 302 Hospital - Recruiting 18 years to 60 years.
- Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection.
TwHF; placebo treatment

HIV Infection Clinical Trial

Bristol-Myers Squibb - Recruiting N/A to 17 years.
- Post-marketing Safety Surveillance Program in HIV-infected Children Exposed to Atazanavir in Europe.

HIV Clinical Trial using (FDC) ELV/COBI/FTC/TDF

Duke University - Recruiting 18 years to 75 years.
- Treatment of Acute HIV Infection With the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate, A Pilot Study of Response to Therapy and HIV Pathogenesis.
(FDC) ELV/COBI/FTC/TDF

HIV Infection Clinical Trial using antiretroviral treatment

Hospital Clinic of Barcelona - Recruiting 18 years or older.
- Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy Instead of a Triple Therapy That Includes Lopinavir/Ritonavir and Lamivudine or Emtricitabine in HIV Patients With Viral Suppression: Controlled Clinical Trial, Open Label, Randomized, of 48 Weeks of Follow-up.
antiretroviral treatment

Hazardous Alcohol Use, Binge Drinking, High Risk Sexual Behaviors Clinical Trial using Computerized brief alcohol intervention with IVR booster calls; Computer delivered brief alcohol intervention; Attention Control

Johns Hopkins University - Recruiting 18 years or older.
- Computerized BI for Binge Drinking HIV At-Risk and Infected African-American Women.
Computerized brief alcohol intervention with IVR booster calls; Computer delivered brief alcohol intervention; Attention Control

High Triglyceride Level, or HIV Infection Clinical Trial using Lovaza

Tufts University - Recruiting 18 years or older.
- The Impact of Omega Three Fatty Acids on Vascular Function in HIV.
Lovaza

HIV Infection, or Pulmonary TB Clinical Trial using ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)

Tuberculosis Research Centre, India - Recruiting 18 years or older.
- A Randomized Controlled Clinical Trial Comparing Daily Vs. Intermittent 6 - Month Short Course Chemotherapy in Reducing Failures & Emergence of Acquired Rifampicin Resistance (ARR) in Patients With HIV and Pulmonary Tuberculosis.
ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)

HIV Infection Clinical Trial

Istituto Superiore di Sanita - Recruiting 18 years to 45 years.
- A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape.

Hepatitis C, Chronic, or HIV Infection Clinical Trial using Adherence questionnaire

Fundacion IMIM - Recruiting 18 years or older.
- Development and Validation of a Questionnaire Measuring Treatment Adherence in Patients With Hepatitis C.
Adherence questionnaire

Tuberculosis, or HIV Infections Clinical Trial using Emtricitabine/tenofovir/efavirenz

African Poverty Related Infection Oriented Research Initiative - Recruiting 18 years to 65 years.
- The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.
Emtricitabine/tenofovir/efavirenz

Infant, Newborn, Diseases, Sepsis, or Puerperal Infection Clinical Trial using Chlorhexidine; Birth canal wipe; sterile water external genital wipe

Centers for Disease Control and Prevention - Recruiting 15 years or older.
- Preventing Serious Neonatal and Maternal Peripartum Infections in Developing Country Settings With a High Prevalence of HIV Infection: Assessment of the Disease Burden and Evaluation of an Affordable Intervention in Soweto, South Africa.
Chlorhexidine; Birth canal wipe; sterile water external genital wipe

HIV Infections Clinical Trial

National Institute of Allergy and Infectious Diseases (NIAID) - Recruiting 18 years to 60 years.
- Evaluation of HIV-Specific Immunological and Virological Responses of HIV-1 Multiply-Exposed Seronegative Individuals.

HIV Infection, or AIDS Clinical Trial using once daily minimum 3-drug regimen of anti-retroviral medications

407 Doctors - Recruiting 18 years or older.
- A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily.
once daily minimum 3-drug regimen of anti-retroviral medications